# PeptideScanner evidence objects: Histrelin

Every published version of the records placed with Histrelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/histrelin.json. Selected public evidence only; not medical advice.

- Objects: 10
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00779103-histrelin-v1"></a>

## ClinicalTrials.gov record NCT00779103

> PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.

- Evidence object: `story:clinicaltrials-gov-nct00779103-histrelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-01-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00779103-histrelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#clinicaltrials-gov-nct00779103-histrelin-v1
- Content SHA-256: `166583b445b011d3536ff7f7cca745941ed79fe0185e3a31b1601e186384bcfb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00779103 ([`ctg-observation-nct00779103-2021-01-08-94c632687e1b`](#source-ctg-observation-nct00779103-2021-01-08-94c632687e1b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin. ([`ctg-observation-nct00779103-2021-01-08-94c632687e1b`](#source-ctg-observation-nct00779103-2021-01-08-94c632687e1b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin. ([`ctg-observation-nct00779103-2021-01-08-94c632687e1b`](#source-ctg-observation-nct00779103-2021-01-08-94c632687e1b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00779103-2021-01-08-94c632687e1b`](#source-ctg-observation-nct00779103-2021-01-08-94c632687e1b))

### Sources

<a id="source-ctg-observation-nct00779103-2021-01-08-94c632687e1b"></a>
- **ClinicalTrials.gov record NCT00779103 · retained source version 2021-01-08:94c632687e1bf618ac93e922bb83d936319de6ff7a7775ebca2914188e136c14** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00779103) (`ctg-observation-nct00779103-2021-01-08-94c632687e1b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00779103." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#clinicaltrials-gov-nct00779103-histrelin-v1 SHA-256: 166583b445b011d3536ff7f7cca745941ed79fe0185e3a31b1601e186384bcfb.

---

<a id="fda-drugs-nda019836-v1"></a>

## Drugs@FDA application NDA019836

> The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019836:v1`
- Evidence domain: Regulatory
- Date in source: 1991-12-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019836/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#fda-drugs-nda019836-v1
- Content SHA-256: `852b053eba50fcdd9934cb635d8eb2499aeea4d98cec14b87d4b52083381f03a`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019836 ([`fda-drugs-nda019836-1991-12-24-8b92e9e54bd4`](#source-fda-drugs-nda019836-1991-12-24-8b92e9e54bd4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients. ([`fda-drugs-nda019836-1991-12-24-8b92e9e54bd4`](#source-fda-drugs-nda019836-1991-12-24-8b92e9e54bd4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients. ([`fda-drugs-nda019836-1991-12-24-8b92e9e54bd4`](#source-fda-drugs-nda019836-1991-12-24-8b92e9e54bd4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019836-1991-12-24-8b92e9e54bd4`](#source-fda-drugs-nda019836-1991-12-24-8b92e9e54bd4))

### Sources

<a id="source-fda-drugs-nda019836-1991-12-24-8b92e9e54bd4"></a>
- **Drugs@FDA application NDA019836 · original submission status AP · 1991-12-24 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019836%22&limit=1) (`fda-drugs-nda019836-1991-12-24-8b92e9e54bd4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019836." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#fda-drugs-nda019836-v1 SHA-256: 852b053eba50fcdd9934cb635d8eb2499aeea4d98cec14b87d4b52083381f03a.

---

<a id="fda-drugs-nda021732-v1"></a>

## Drugs@FDA application NDA021732

> The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021732:v1`
- Evidence domain: Regulatory
- Date in source: 2004-10-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021732/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#fda-drugs-nda021732-v1
- Content SHA-256: `d0645ad3109fb24c8aee3233547ee53f8c0739ed6fa00797a27d577d52bd1d11`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021732 ([`fda-drugs-nda021732-2004-10-12-85afe307ada3`](#source-fda-drugs-nda021732-2004-10-12-85afe307ada3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients. ([`fda-drugs-nda021732-2004-10-12-85afe307ada3`](#source-fda-drugs-nda021732-2004-10-12-85afe307ada3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients. ([`fda-drugs-nda021732-2004-10-12-85afe307ada3`](#source-fda-drugs-nda021732-2004-10-12-85afe307ada3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021732-2004-10-12-85afe307ada3`](#source-fda-drugs-nda021732-2004-10-12-85afe307ada3))

### Sources

<a id="source-fda-drugs-nda021732-2004-10-12-85afe307ada3"></a>
- **Drugs@FDA application NDA021732 · original submission status AP · 2004-10-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021732%22&limit=1) (`fda-drugs-nda021732-2004-10-12-85afe307ada3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021732." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#fda-drugs-nda021732-v1 SHA-256: d0645ad3109fb24c8aee3233547ee53f8c0739ed6fa00797a27d577d52bd1d11.

---

<a id="fda-drugs-nda022058-v1"></a>

## Drugs@FDA application NDA022058

> The official Drugs@FDA dataset lists original submission 1 for NDA 022058 with status AP dated 2007-05-03, and names histrelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022058:v1`
- Evidence domain: Regulatory
- Date in source: 2007-05-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022058/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#fda-drugs-nda022058-v1
- Content SHA-256: `7c604a2a38b16eb225c16a1aff38fc18fb963304c32c2ea83a0f5ed5e0eeced7`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022058 ([`fda-drugs-nda022058-2007-05-03-5ff8727bd2ec`](#source-fda-drugs-nda022058-2007-05-03-5ff8727bd2ec))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022058 with status AP dated 2007-05-03, and names histrelin acetate among the application record's active ingredients. ([`fda-drugs-nda022058-2007-05-03-5ff8727bd2ec`](#source-fda-drugs-nda022058-2007-05-03-5ff8727bd2ec))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022058 with status AP dated 2007-05-03, and names histrelin acetate among the application record's active ingredients. ([`fda-drugs-nda022058-2007-05-03-5ff8727bd2ec`](#source-fda-drugs-nda022058-2007-05-03-5ff8727bd2ec))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022058-2007-05-03-5ff8727bd2ec`](#source-fda-drugs-nda022058-2007-05-03-5ff8727bd2ec))

### Sources

<a id="source-fda-drugs-nda022058-2007-05-03-5ff8727bd2ec"></a>
- **Drugs@FDA application NDA022058 · original submission status AP · 2007-05-03 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022058%22&limit=1) (`fda-drugs-nda022058-2007-05-03-5ff8727bd2ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022058." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#fda-drugs-nda022058-v1 SHA-256: 7c604a2a38b16eb225c16a1aff38fc18fb963304c32c2ea83a0f5ed5e0eeced7.

---

<a id="federal-register-03-20949-v1"></a>

## Federal Register notice 03-20949

> The Federal Register published notice 03-20949, attributed to FDA and its parent HHS department, on 2003-08-18. Its official title is “Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Histrelin and Secretin.

- Evidence object: `story:federal-register-03-20949:v1`
- Evidence domain: Regulatory
- Date in source: 2003-08-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-03-20949/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#federal-register-03-20949-v1
- Content SHA-256: `7c08fedd431dfbad95bccacc43bb888b0a2d5b2bb37ea047a5952ef9c2a4a5ef`

### Claims and source pins

#### Headline

Federal Register notice 03-20949 ([`federal-register-03-20949-30e522866ea9`](#source-federal-register-03-20949-30e522866ea9))

#### Summary

The Federal Register published notice 03-20949, attributed to FDA and its parent HHS department, on 2003-08-18. Its official title is “Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Histrelin and Secretin. ([`federal-register-03-20949-30e522866ea9`](#source-federal-register-03-20949-30e522866ea9))

#### Paragraph 1

The Federal Register published notice 03-20949, attributed to FDA and its parent HHS department, on 2003-08-18. Its official title is “Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Histrelin and Secretin. ([`federal-register-03-20949-30e522866ea9`](#source-federal-register-03-20949-30e522866ea9))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-03-20949-30e522866ea9`](#source-federal-register-03-20949-30e522866ea9))

### Sources

<a id="source-federal-register-03-20949-30e522866ea9"></a>
- **Federal Register notice 03-20949 · published 2003-08-18 · Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2003-08-18/pdf/03-20949.pdf) (`federal-register-03-20949-30e522866ea9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 03-20949." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#federal-register-03-20949-v1 SHA-256: 7c08fedd431dfbad95bccacc43bb888b0a2d5b2bb37ea047a5952ef9c2a4a5ef.

---

<a id="pubmed-pmid-19228148-histrelin-v1"></a>

## A review of the use of histrelin acetate in the treatment of prostate cancer.

> PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19228148-histrelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19228148-histrelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-19228148-histrelin-v1
- Content SHA-256: `6e164d4ff95ef0b47d8204b83ba4ea904b72c52cc08da4a021052bb6cf9a6226`

### Claims and source pins

#### Headline

A review of the use of histrelin acetate in the treatment of prostate cancer. ([`pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f`](#source-pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f))

#### Summary

PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f`](#source-pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f))

#### Paragraph 1

PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f`](#source-pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f`](#source-pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f))

### Sources

<a id="source-pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f"></a>
- **A review of the use of histrelin acetate in the treatment of prostate cancer. · retained source version 1:2012-11-15:current:9f9e6f88d18fd227a203ad6f25e1e86f28402d4d36e82140e01970f777c543f2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19228148/) (`pubmed-observation-pmid-19228148-2012-11-15-9f9e6f88d18f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A review of the use of histrelin acetate in the treatment of prostate cancer." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-19228148-histrelin-v1 SHA-256: 6e164d4ff95ef0b47d8204b83ba4ea904b72c52cc08da4a021052bb6cf9a6226.

---

<a id="pubmed-pmid-20329807-histrelin-v1"></a>

## Histrelin: in advanced prostate cancer.

> PubMed lists PMID 20329807 in Drugs as Journal Article, Review, with publication-date metadata of 2010-03-26 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20329807-histrelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20329807-histrelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-20329807-histrelin-v1
- Content SHA-256: `d9308c257ab4ecfc6aee02a4dd2dcf5d1bfc337b812e85c4135944313022a6d3`

### Claims and source pins

#### Headline

Histrelin: in advanced prostate cancer. ([`pubmed-observation-pmid-20329807-2021-10-20-8a4108973151`](#source-pubmed-observation-pmid-20329807-2021-10-20-8a4108973151))

#### Summary

PubMed lists PMID 20329807 in Drugs as Journal Article, Review, with publication-date metadata of 2010-03-26 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20329807-2021-10-20-8a4108973151`](#source-pubmed-observation-pmid-20329807-2021-10-20-8a4108973151))

#### Paragraph 1

PubMed lists PMID 20329807 in Drugs as Journal Article, Review, with publication-date metadata of 2010-03-26 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20329807-2021-10-20-8a4108973151`](#source-pubmed-observation-pmid-20329807-2021-10-20-8a4108973151))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20329807-2021-10-20-8a4108973151`](#source-pubmed-observation-pmid-20329807-2021-10-20-8a4108973151))

### Sources

<a id="source-pubmed-observation-pmid-20329807-2021-10-20-8a4108973151"></a>
- **Histrelin: in advanced prostate cancer. · retained source version 1:2021-10-20:current:8a41089731514dab539ad8962179088b8d996b2ae5606c92dec552b1afaea8ee** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20329807/) (`pubmed-observation-pmid-20329807-2021-10-20-8a4108973151`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Histrelin: in advanced prostate cancer." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-20329807-histrelin-v1 SHA-256: d9308c257ab4ecfc6aee02a4dd2dcf5d1bfc337b812e85c4135944313022a6d3.

---

<a id="pubmed-pmid-2051345-histrelin-v1"></a>

## Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist.

> PubMed lists PMID 2051345 in Journal of pharmaceutical sciences as Journal Article, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2051345-histrelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2051345-histrelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-2051345-histrelin-v1
- Content SHA-256: `296a4718ab7dc75331b00a04b465439166941b809427180d8dba1da9d092bb8e`

### Claims and source pins

#### Headline

Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist. ([`pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60`](#source-pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60))

#### Summary

PubMed lists PMID 2051345 in Journal of pharmaceutical sciences as Journal Article, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60`](#source-pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60))

#### Paragraph 1

PubMed lists PMID 2051345 in Journal of pharmaceutical sciences as Journal Article, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60`](#source-pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60`](#source-pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60))

### Sources

<a id="source-pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60"></a>
- **Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist. · retained source version 1:2019-07-10:current:b4396c273f604fa65e817dd4c5b857f2a58f0e6d111b45d15611b1ca938f053c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2051345/) (`pubmed-observation-pmid-2051345-2019-07-10-b4396c273f60`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-2051345-histrelin-v1 SHA-256: 296a4718ab7dc75331b00a04b465439166941b809427180d8dba1da9d092bb8e.

---

<a id="pubmed-pmid-25899147-histrelin-v1"></a>

## Histrelin for central precocious puberty-a single surgeon experience.

> PubMed lists PMID 25899147 in The Journal of surgical research as Journal Article, with publication-date metadata of 2015-03-30 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25899147-histrelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25899147-histrelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-25899147-histrelin-v1
- Content SHA-256: `f13c1ca6d81e79ca960dfea41e8ac00f7d73e2cfa6b13cbad637d6f55ae437eb`

### Claims and source pins

#### Headline

Histrelin for central precocious puberty-a single surgeon experience. ([`pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06`](#source-pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06))

#### Summary

PubMed lists PMID 25899147 in The Journal of surgical research as Journal Article, with publication-date metadata of 2015-03-30 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06`](#source-pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06))

#### Paragraph 1

PubMed lists PMID 25899147 in The Journal of surgical research as Journal Article, with publication-date metadata of 2015-03-30 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06`](#source-pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06`](#source-pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06))

### Sources

<a id="source-pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06"></a>
- **Histrelin for central precocious puberty-a single surgeon experience. · retained source version 1:2026-01-28:current:644c4fbd7a06a556ccb1bdf9c6aeb643e4768a1bf50a76d6419329213ca0f919** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25899147/) (`pubmed-observation-pmid-25899147-2026-01-28-644c4fbd7a06`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Histrelin for central precocious puberty-a single surgeon experience." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-25899147-histrelin-v1 SHA-256: f13c1ca6d81e79ca960dfea41e8ac00f7d73e2cfa6b13cbad637d6f55ae437eb.

---

<a id="pubmed-pmid-7684676-histrelin-v1"></a>

## Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.

> PubMed lists PMID 7684676 in Drugs as Journal Article, Review, with publication-date metadata of 1993-04 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7684676-histrelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7684676-histrelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-7684676-histrelin-v1
- Content SHA-256: `3e4b06998b16d7662b318b53a84d4e320cd7f03e5da70ae70b71c4393b90f386`

### Claims and source pins

#### Headline

Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty. ([`pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c`](#source-pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c))

#### Summary

PubMed lists PMID 7684676 in Drugs as Journal Article, Review, with publication-date metadata of 1993-04 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c`](#source-pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c))

#### Paragraph 1

PubMed lists PMID 7684676 in Drugs as Journal Article, Review, with publication-date metadata of 1993-04 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c`](#source-pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c`](#source-pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c))

### Sources

<a id="source-pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c"></a>
- **Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty. · retained source version 1:2018-11-13:current:644d4fad787c122d84735ecc39d838e4fc967b8429188d1be1356d0e323003f0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7684676/) (`pubmed-observation-pmid-7684676-2018-11-13-644d4fad787c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/histrelin.json#pubmed-pmid-7684676-histrelin-v1 SHA-256: 3e4b06998b16d7662b318b53a84d4e320cd7f03e5da70ae70b71c4393b90f386.

